UNION, N.J., March 04, 2025 (GLOBE NEWSWIRE) — NanoNewron, LLC (“NanoNewron” or the “Company”), a pioneering biotechnology company developing innovative, humanized biologics that cross the blood-brain barrier (BBB) to treat Alzheimer’s and other central nervous system (CNS) neurodegenerative diseases, announced today that Marco Taglietti, M.D., has been appointed Chief Executive Officer, effective February 1st, 2025.
“I am excited to have Marco joining NanoNewron, and to lead NanoNewron into the future,” said Luciano D’Adamio, M.D., PhD, NanoNewron’s co-founder. “I look forward to working closely with him as we continue to advance the development of our lead compound for the treatment of Alzheimer’s Disease and other neurodegenerative diseases. Marco brings to the position an outstanding experience in drug development and a successful track record in leading pharma organizations. In his long career, he brought to the market more than 35 drugs and devices, including several CNS products.”
“NanoNewron is a company with an innovative technology, a very promising product and a great potential,” said Marco Taglietti, M.D. “I am honored and excited to be taking on the role of CEO. There is still a dire need for more effective treatments for Alzheimer’s Disease. Despite decades of research, the current treatments only offer temporary improvements in symptoms and just a modest slowdown of cognitive decline. Currently there is no treatment that blocks the underlying progression of cognitive deterioration in Alzheimer’s disease, let alone cure it. The product developed at NanoNewron, a powerful anti-TNF-alpha nanobody, promises to transform the treatment of Alzheimer’s in the same way that TNF-alpha inhibitors transformed the treatment of systemic inflammatory diseases such as Crohn’s Disease or Rheumatoid Arthritis.”
Marco Taglietti, M.D. has served as President, Chief Executive Officer and Director of SCYNEXIS, Inc., a biotechnology company …
